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Abstract
A more detailed insight into disease mechanisms of multiple sclerosis (MS) is crucial for the development of new and more
effective therapies. MS is a chronic inflammatory autoimmune disease of the central nervous system. The aim of this study is
to identify novel disease associated proteins involved in the development of inflammatory brain lesions, to help unravel
underlying disease processes. Brainstem proteins were obtained from rats with MBP induced acute experimental
autoimmune encephalomyelitis (EAE), a well characterized disease model of MS. Samples were collected at different time
points: just before onset of symptoms, at the top of the disease and following recovery. To analyze changes in the
brainstem proteome during the disease course, a quantitative proteomics study was performed using two-dimensional
difference in-gel electrophoresis (2D-DIGE) followed by mass spectrometry. We identified 75 unique proteins in 92 spots
with a significant abundance difference between the experimental groups. To find disease-related networks, these
regulated proteins were mapped to existing biological networks by Ingenuity Pathway Analysis (IPA). The analysis revealed
that 70% of these proteins have been described to take part in neurological disease. Furthermore, some focus networks
were created by IPA. These networks suggest an integrated regulation of the identified proteins with the addition of some
putative regulators. Post-synaptic density protein 95 (DLG4), a key player in neuronal signalling and calcium-activated
potassium channel alpha 1 (KCNMA1), involved in neurotransmitter release, are 2 putative regulators connecting 64% of the
identified proteins. Functional blocking of the KCNMA1 in macrophages was able to alter myelin phagocytosis, a disease
mechanism highly involved in EAE and MS pathology. Quantitative analysis of differentially expressed brainstem proteins in
an animal model of MS is a first step to identify disease-associated proteins and networks that warrant further research to
study their actual contribution to disease pathology.
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Introduction
MS is an inflammatory autoimmune disease of the central
nervous system (CNS) in which genetic, environmental and
immunological factors are involved [1,2]. The disease is
characterized by blood brain barrier (BBB) breakdown, demye-
lination, oligodendrocyte apoptosis, progressive axonal damage
and reactive astrogliosis [3–5]. These pathological hallmarks are
present in the multifocal inflammatory lesions of the CNS,
primarily localized in the white matter. The infiltration of
autoreactive T cells, B cells and macrophages, and the production
of pro-inflammatory cytokines are known to take part in the
formation of inflammatory CNS lesions [4,6–9]. Still, the exact
cause and underlying molecular mechanisms remain poorly
understood, but are crucial in the search for new therapeutic
options. A proteomics approach was chosen to get more insight in
the molecular processes of MS.
Proteomics studies are valuable to get an overview of protein
expression in cells, tissues or organisms. These protein expression
profiles can provide indications towards molecular mechanisms
involved in normal and disease processes. In the past, gel-based
proteome studies of brain [10] and cerebrospinal fluid (CSF) [11–
14] were carried out by comparison of intensities of (silver) stained
gel spots, a procedure that may suffer from experimental
variability and poor reproducibility. Only adequate quantitative
approaches will allow the analysis of disease processes over time in
the brain or CSF during neuroinflammation. Two-dimensional
fluorescence difference gel electrophoresis (2D-DIGE) is a very
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the utilization of fluorescently labelled samples on the same gel,
and the application of an internal standard for intra- and inter-gel
comparisons and normalization.
In MS research, some quantitative proteomics studies have
already been completed [15–17]. Looking at 2D-DIGE experi-
ments, mostly biomarker studies on human CSF were performed
[18–22]. In one proteomics study in MS research, a comparison
between multiple plaque-types was performed to obtain new
therapeutic targets [23], although not by 2D-DIGE. Post-mortem
MS samples are often a snapshot of longstanding disease.
Therefore, a well characterized homogeneous animal model,
experimental autoimmune encephalomyelitis (EAE), was selected
for this study to obtain a sample of the inflammatory lesions. Only
2 experiments were published in which CNS tissue of EAE
animals was used for a 2D-DIGE study [24,25]. In these studies
protein expression was compared between two experimental
groups. To get a better understanding of the pathomechanisms
in MS and EAE, we decided to use experimental groups at
different time points during the disease.
Here we report disease stage-specific variations in brain protein
expression found in samples from different time points during
acute EAE, a well characterized animal model of MS. The
brainstem of this model was selected to focus on CNS
inflammatory pathways involved in the lesion development and
regulation of EAE, as it was shown that disease related
macrophage infiltration at the onset of acute Lewis rat EAE was
mainly localized to the caudal part of the brainstem [26]. We
performed a 2D-DIGE study to quantitatively compare protein
levels at different disease stages. Samples were obtained before
onset of the symptoms, at the top of the disease and after recovery.
This allows us to create graphs of brain protein levels over time.
We were able to identify 75 unique proteins present in 92
differential gel spots. All of these proteins were analyzed with
Ingenuity Pathway Analysis (IPA) software to disclose connections
between these proteins, and thus define pathways that could be
involved in the molecular mechanisms of MS.
Results
EAE brain proteome analysis by 2D-DIGE/mass
spectrometry
Detergent-soluble protein extracts were isolated for a quantita-
tive 2D-DIGE study to identify differential proteins in the
brainstem of EAE-animals and controls at different stages of the
disease. Controls were CFA injected, whereas acute EAE was
induced by immunization with myelin basic protein (MBP)
(Figure 1). The EAE animals were divided into three groups:
before onset, at the top, and following recovery of the disease. We
identified proteins in 92 differential gelspots (ANOVA#0.05) with
DeCyder 7.0 gel analysis software and nano-LC-mass spectrom-
etry (Figure 2). The difference in fluorescence intensity, as reported
in the DeCyder software, indicates a change in expression,
turnover and/or protein modification. Sixty-nine of the 92
differential protein spots were even more stringently regulated
(ANOVA # 0.01, bold in Table S1). A total of 130 proteins were
identified in these 92 spots, since multiple proteins can be present
in one gelspot (Table 1). Furthermore, 24 of these proteins were
present in multiple (2–10) spots. Overall, 75 unique proteins were
identified.
To get a better view on the expression profile of these spots
along the disease course, a cluster analysis was performed. Using
self organizing maps (SOM) analysis, spots that have the same
expression patterns during the disease are grouped together
(Figure 3). The average ratio and T-test, for the six possible
comparisons between the four conditions included in this study,
provided detailed information on the time course of the proteome
changes induced in the inflamed brain (Table S2).
Identity and validity of differential proteins
BBB disruption, astrocyte activation and macrophage infiltra-
tion are processes known to occur in MS and acute EAE. We
focused on proteins related to these disease processes to verify the
experimental setup and analyses. Indeed, serum albumin (ALB,
e.g. spot 874), glial fibrillary acidic protein (GFAP, e.g. spot 1397)
and macrophage-capping protein (CAPG, spot 1906) represent
these pathological hallmarks and are all upregulated at the top of
the disease (Figure 4). An ED-1 macrophage staining on spinal
cord slices verified the infiltration of macrophages in the CNS
(Figure 5A). In contrast to the absence of macrophages in controls
and just prior to disease onset, macrophage infiltration was
significantly increased at the top of the disease (Figure 5B), a
similar pattern as seen for CAPG. Identification of differential
proteins that represent processes actively involved in the disease,
verifies our experimental design and the ability to pick up disease-
related proteins.
The expression pattern of 29,39-cyclic-nucleotide 39-phosphodi-
esterase (CNP), an abundant myelin protein, was significantly
decreased in the inflamed brain (Figure 4, spot 1656 and 1685).
This could be indicative for myelin loss. We confirmed this CNP
decrease with immunohistochemistry (IHC) and western blot (WB)
(Figure 5). IHC was performed and quantified at the site of
inflammation. CNP was significantly decreased at the top of the
disease and after recovery (Figure 5C). Furthermore, a fluorescent
quantitative anti-CNP WB revealed two bands, consistent with
CNP1 (46 kDa) and CNP2 (48 kDa). Both CNP1 and CNP2 were
significantly decreased at top of the disease compared to control
animals (fold change 21.5460.03 and 21.4060.05 respectively).
In conclusion, with two independent techniques, we were able to
confirm the 2D-DIGE expression data for CNP.
Principal component analysis and Ingenuity Pathway
Analysis
Principal component analysis (PCA) is an unsupervised
multivariate method used to analyze the variability between
Figure 1. Clinical scores and weight changes of EAE and control
animals. EAE was induced by injection of MBP in CFA (bars and
squares). Control animals were CFA injected (dots). The controls
showed no clinical symptoms. Each value represents the mean 6
standard deviation of n animals: control day1-15, n=3; EAE day1–9,
n=9; day10–14, n=6 and day15–18, n=3.
doi:10.1371/journal.pone.0035544.g001
Identification of Protein Networks in EAE
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35544experimental groups. A dimension reduction is applied previous to
classification, reducing the possibly correlated variables (differen-
tial spots) to a set of uncorrelated variables. In this way a principal
component represents a linear combination of the differential
spots. Each sample (spotmap) is represented in the PCA plot with
respect to the principal components. A PCA was performed on our
dataset and shows clustering of the samples according to the
disease stage. A clear separation between the early disease stage
(before onset of the disease) and the late disease stages (top and
recovery) is evident (Figure 6). Furthermore, samples from the top
of the disease are separated from recovery samples. In contrast, the
control and onset samples were not separated; implicating that
differences in brain protein expression were not sufficient for
separation between these two conditions.
Human homologues of the 75 unique proteins identified here
were subsequently analyzed with IPA, a software tool capable of
mapping proteins onto existing networks and pathways. Cellular
compartments as designated by IPA (gene ontology based)
indicated that the majority of identified proteins (76%) were
cytoplasmic in origin (Figure 7). Mapping of our proteins onto
biological pathways and disease networks demonstrated that 16
proteins were linked to nervous system development and function
(p-value: 2.47E-05–4.50E-02), and that 53 of the 75 proteins were
associated with neurological disease (p-value: 1.35E-15–4.50E-02).
Post synaptic density protein 95 (DLG4) and amyloid precursor
protein (APP) appear to be central points in the IPA networks
identified here, but they were not detected in the 2D-DIGE study.
Another possibility in the IPA software was the comparison of
the 75 unique proteins to a list of MS-related proteins present in
the IPA knowledge base. As expected due to technical restrictions,
only one of these mostly membrane-associated MS-related
proteins was also identified in our 2D-DIGE study, protein
disulfide-isomerase A3 (PDIA3, spot 1149) (Figure 4). However,
fifty-eight of our differential proteins were linked to these MS-
related proteins, mostly by downstream biochemical pathways
Figure 2. 2D-DIGE gel image. The 92 spots presented have a shift in abundance over the four experimental conditions (control, disease onset, top,
and recovery) (ANOVA # 0.05). Spots were picked from preparative 2D-gels and proteins identified by nano-LC-ESI-mass spectrometry. The proteins
were identified with significant MASCOT and SEQUEST scores. Spots are numbered as in Table S1.
doi:10.1371/journal.pone.0035544.g002
Table 1. Identification of differentially expressed protein
spots (A#0.05).
# protein
identifications/spot # identified spots # proteins
16 3 6 3
22 2 4 4
35 1 5
42 8
Total 92 identified spots 130 identified proteins
doi:10.1371/journal.pone.0035544.t001
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potassium channel alpha 1 (KCNMA1) were MS-related proteins
from the IPA knowledgebase with a strong relation to our data.
Together with DLG4 and APP, they were selected for building
focus networks of our dataset. These networks suggest an
integrated regulation of the identified proteins with the addition
of some putative regulators. They are a model for the effects of
these four proteins on our dataset (Figure 8 and Table S3). Forty-
eight proteins (64%) of the 2D-DIGE dataset were directly linked
to DLG4 and/or KCNMA1. Forty-two (56%) were linked to AGT
and 40 (53.3%) to APP. In the AGT network another important
potential regulator of our dataset was identified, being tumor
protein p53 (TP53).
We confirmed the presence of DLG4 and KCNMA1 in our
brain samples performing a quantitative fluorescent immunoblot-
ting (Figure 9). By using a combination of a total protein staining
and an immunostaining on western blot, it is possible to correct for
differences in total protein loading. Fluorescent stains allow for
peak detection and quantification. For both DLG4 and
KCNMA1, presence of the protein in our samples could be
established, but no expression differences were detected between
disease stages. This in part explains why these proteins were not
picked up in our 2D-DIGE analyses. Even though they are not
differentially expressed, their presence in the centre of the IPA
networks suggests a role for DLG4 and KCNMA1 as central
regulators in the molecular mechanisms of disease progression.
KCNMA1 is a calcium-activated potassium channel with a direct
connection to CAPG, a protein involved in actin-based cell
motility and thus important for macrophage functions such as
migration and myelin phagocytosis, processes known to be highly
involved in MS and EAE pathology [7]. We demonstrated that
specific blocking of KCNMA1 using paxillin significantly reduced
myelin phagocytosis by LPS activated macrophages
(217.79610.67%, p,0.01, Figure 10). This nicely illustrates that
Figure 3. SOM analysis. A SOM analysis was performed to group spots with a similar expression pattern, in this way clustering the spots that are
regulated in the same way. Sixteen clusters were obtained, one (12) containing no spots. The X-axis chronologically displays the experimental groups
(C-O-T-R) while the Y-axis displays the log standardized abundance (scale is not identical for the different clusters). The cluster number, quality value
(q) and number of spots present in the cluster (no) are indicated above the graphs.
doi:10.1371/journal.pone.0035544.g003
Figure 4. Protein expression patterns over the disease course.
2D-DIGE expression profiles: ALB (spot 874), PDIA3 (spot 1149), GFAP
(spot 1397), CNP (spot 1656 and 1685) and CAPG (spot 1906). The log
standard abundance (the relative abundance change normalized to
signals in internal standard specific for each spot) is indicated for
control, onset, top and recovery samples.
doi:10.1371/journal.pone.0035544.g004
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in the disease process.
Discussion
We identified proteins present in 92 differential spots of the
inflamed brain of EAE animals by means of a comparative 2D-
DIGE proteomics analysis. Changes in the abundance of these 92
spots can discriminate between early (before onset) and late (top
and recovery) disease stages by PCA of their values in the sample
spotmaps. Seventy-five unique proteins were identified in these 92
differential spots by means of mass spectrometry. Some of these
proteins represent known disease processes such as BBB disruption
(ALB), astrocyte activation (GFAP) and macrophage infiltration
(CAPG). Others are not yet linked to MS, and warrant further
research. An in-depth network evaluation was performed for all 75
unique proteins.
Seventy percent of our identifications (53/75 proteins) are part
of the biological pathway of neurological disease. One such
example is the decrease in GABA transaminase (ABAT, spot 1437
and 1439), succinate-semialdehyde dehydrogenase (ALDH5A1,
spot 1428) and mitochondrial glutamate dehydrogenase 1
(GLUD1, spot 1316 and 1331). Both ABAT and ALDH5A1 are
enzymes responsible for the degradation of GABA, the principal
inhibitory neurotransmitter of the CNS that is also involved in
inflammation [27]. When these enzymes decrease, GABA levels
will increase. GLUD1 is an enzyme responsible for the
interconversion of glutamate and alpha-ketoglutarate. A decrease
Figure 5. Validation of the 2D-DIGE results. Immunohistochemistry was performed to demonstrate the presence of macrophages and CNP.
Macrophage (ED-1) and CNP immunostaining of rat spinal cords (same animals as for 2D-DIGE) from control, and EAE rats before disease onset, top
and recovery are shown in panel A. These IHC stainings were quantified (Panel B and C), and expression levels compared by Dunn’s multiple
comparison test (GraphPad Prism4). The error bars indicate standard deviations of measurements performed at least in triplicate. *: significant
difference, p,0.01 and **: significant difference, p,0.001. In Panel D, a quantitative 1D CNP immunoblot of EAE brainstem homogenate from control
and disease top is shown. An overview of the fluorescent total protein staining, anti-CNP immunostaining, the fluorescent overlay of both (red and
green overlay), and finally a representation of the fluorescent signals as processed with ImageQuant TL software (GE Healthcare). The red curve
corresponds with the total protein content and the green curve with the CNP fluorescence. Both a representative control animal (c) and one at the
disease top (t) are presented.
doi:10.1371/journal.pone.0035544.g005
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mitter reported to be involved in MS excitotoxicity [9] and the
precursor of GABA. Overall, these proteome changes indicate an
increase of GABA at the top of the disease. Dysregulation of the
GABA pathway in MS brains has been described in several studies
and the implications of these findings have been tested in EAE
[27,28].
Four central network-nodes were suggested by IPA. DLG4 and
APP are nodes from the IPA networks of our data, while
KCNMA1 and AGT are MS-related proteins in the IPA
knowledge base, with a strong relationship to our data. APP is
an integral membrane protein that is concentrated at neuronal
synapses. It can be synthesized by microglia, not only in response
to direct nerve injury but also in immune-mediated disease such as
EAE [29]. A role for APP in immune and repair mechanisms of
the CNS is suggested [29]. A second network is build around
AGT, a protein produced by astrocytes in the brain [30]. It is part
of the renin-angiotensin system (RAS) that affects the immune
response in general and the neuroinflammatory processes in the
context of EAE [31]. TP53, a well-known tumor suppressor that
responds to cellular stress and can induce apoptosis and changes in
metabolism is also present as a regulator in this network. TP53 was
recently described to be an important ‘network-hub’ that interacts
with a lot of genes associated with MS, indicating a role for this
protein in the disease, namely the expansion of autoimmune cell
clones [32]. Sixty-four percent of our data are connected to DLG4
and/or KCNMA1, which highlights their possible role in EAE/
MS. DLG4 is a membrane-associated protein implicated in the
clustering of receptors, ion channels and associated signaling
molecules in the post-synaptic membrane. It is a key player in
neuronal signaling. KCNMA1 is an IPA MS-related protein
involved in neurotransmitter release. The channel activity
increases during hypoxia and decreases in response to reactive
oxygen species (ROS) [33]. Mitochondrial ion channels play an
important role in cellular events such as apoptosis (caused by
increased mitochondrial membrane permeability), exocytosis and
synaptic transmission and are believed to contribute to cytoprotec-
tion [33]. Both DLG4 and KCNMA1 are key regulation proteins
of mitochondrial enzyme complexes involved in the cellular
response to oxidative stress, a process that is also described in
EAE/MS [34]. We were able to detect DLG4 and KCNMA1 in
our samples, but they were not differential between the
experimental groups. This could indicate that the activation of
these molecules does not influence their expression. The
alterations in their downstream molecules however suggest that
these pathways are activated during the different disease stages
and thus involved in disease mechanisms. Indeed, DLG4
immunoreactivity in both gray and white matter of EAE spinal
cord tissue was reciprocally associated with damage of postsynaptic
structures and directly associated with disease activity. When EAE
animals were in remission, DLG4 expression partly restored,
further emphasizing the actual involvement of the DLG4 pathway
in disease [35]. Furthermore, we showed that specific blocking of
KCNMA1 in macrophages decreased the ability of macrophages
to phagocytose myelin, a pathological hallmark of MS and EAE
lesions. The above documented functional role of DLG4 and
KCNMA1 in EAE indicates that these networks could be
biologically important for MS pathology and warrants further
research.
Previously a quantitative iTRAQ study was reported comparing
EAE spinal cord proteome between EAE and control animals
[17]. Six proteins were identified in common with our study (ALB,
ANXA3, LAP3, PDIA3, PMSE2 and TF). These 6 proteins show
an increased abundance during the disease in the iTRAQ study as
well as in our study. Han et al. [23] performed a proteomic study
on MS tissue, comparing different MS lesion types. They reported
a total of 2302 proteins related to MS plaques of which 158, 416
and 236 proteins were unique to acute plaques, chronic active
plaques and chronic plaques respectively. Sixty-four of the 75
Figure 6. Unsupervised multivariate analysis discriminating
between early and late groups. PCA reduces the dimensionality of a
multidimensional analysis and displays the two principle components
that can distinguish between the two largest sources of variation within
the dataset (92 spots, ANOVA # 0.05). Principle component analysis
clustering the 12 individual spotmaps into the four conditions by two
principle components: PC1, which distinguishes 90% of the variance,
and PC2 distinguishes an additional 3.8% of the variance.
doi:10.1371/journal.pone.0035544.g006
Figure 7. GO-Compartments. The 75 unique proteins (ANOVA #
0.05) were categorized according to the subcellular compartment
(extracellular space, plasma membrane, cytoplasm, nucleus, and
unknown). Information was collected from Gene ontology by IPA.
Percentages are presented.
doi:10.1371/journal.pone.0035544.g007
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Han et al., all but one (DSP is only present in chronic active
lesions) are common for the different lesion types. The 11 unique
proteins of our study are ACTB, ACTR3, ANXA3, EEF1A1,
GNB1, Ifi47, LOC674678, PTPN1, STXBP1, TUBA1A and
TUBB1. We believe that all 75 proteins reported here warrant
further evaluation, as the data of Han et al. in contrast to our data
are not quantitative and non of our 75 proteins were functionally
evaluated.
The analysis of the brainstem proteome during EAE identified
significant differences in the levels of proteins involved in
mitochondrial energy production, apoptosis, antioxidant activity,
cytoskeleton regulation and the immune system. The in depth
network analysis by IPA as described here adds a major value to
2D-DIGE studies and the combination of both technologies is a
prerequisite to find common regulators that extend even the
limitations of the proteomics technology. Some proteins may play
central roles through functional regulation without being differ-
entially expressed. Still, IPA analysis helps to reveal pathways
involved in the disease process and thereby also potentially
involved proteins that were not picked up directly by 2D-DIGE
analysis. This strategy helps generate new hypotheses and to select
unknown targets in pathways with relevance to MS.
In conclusion, the brain proteome study as presented here
identified biological events involved in neuroinflammation that
may be important during EAE, and also in MS. IPA analysis
provides network information on the differentially expressed
proteins in the 2D-DIGE study and enables the detection of
proteins that cannot be picked up by a gel-based technology due to
the technical restrictions favoring soluble, mostly cytoplasmic
proteins [36,37]. The focus on disease-related networks in this
work enables us to select several relevant topics in MS for further
Figure 8. Ingenuity pathway analysis networks build with focus proteins. The DLG4-KCNMA1 network (Panel A), APP-ACTB network (Panel
B) and AGT-TP53 network (Panel C) are represented. These networks were obtained using the IPA-KB by linking proteins from the data-set (75 unique
proteins) to the focus proteins. Nodes containing proteins identified in the dataset have a grey fill.
doi:10.1371/journal.pone.0035544.g008
Figure 9. Western blot analysis of DLG4 and KCNMA1. A quantitative fluorescent western blot was performed to analyze the presence and
expression levels of KCNMA1 (Panel A) and DLG4 (Panel B). By means of peak detection, the normalized peak volumes were used for quantification.
No significant difference was found in expression levels, but both proteins were detected in the samples of the 2D-DIGE experiment. All animals were
included in the WB analysis; control (C), onset (O), top (T) and recovery (R).
doi:10.1371/journal.pone.0035544.g009
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allows the selection of targets for therapy.
Materials and Methods
Sample Collection
EAE was induced in 7 week-old female Lewis-rats by
subcutaneous immunization with myelin basic protein (MBP) in
Complete Freunds Adjuvant (CFA) [26]. Animals were weighted
and scored daily according to the following scale 0, no
neurological abnormalities; 0.5, partial loss of tail tonus; 1,
complete loss of tail tonus; 2, hind limb paresis; 3, hind limb
paralysis; 4, moribund; 5, death. Before disease onset (9 dpi), at the
top (14 dpi) and after recovery (18 dpi) three animals were
sacrificed and transcardially perfused to obtain blood-free brain
stems (5 mM EDTA in PBS pH 7.2 with Complete Protease
Inhibitor (Roche)). Control animals (n=3) were injected with CFA
only and sacrificed at 15 dpi. After isolation, all tissues were frozen
in liquid nitrogen and subsequently stored at 280uC. This study
was in strict accordance with the EU legislation, Directive 86/
609/EEC. The protocol was approved by, and carried out in strict
agreement with the recommendations of, the local Ethical
Committee for Animal Experiments of Hasselt University (permit
number: 201023).
Protein Extraction
Proteins were extracted as described by Sizova et al. [38].
Briefly, brainstems were lyophilized, crushed (Kontes tissue
grinder) and proteins extracted before ultracentrifugation. Samples
were then desalted and the buffer was exchanged to labeling buffer
(7 M urea, 2 M thiourea, 4% w/v CHAPS in 30 mM Tris HCl
pH 8.5) using ultrafreeH-MC PLCC centrifugal filter units
(Millipore, cut-off 5 kDa). Protein concentration was determined
using the 2D Quant kit (Amersham Biosciences) and aliquots were
stored at 280uC.
Labeling
Minimal labeling with N-hydroxysuccinimidyl-ester dyes Cy2,
Cy3 and Cy5 (GE healthcare) was performed as described by the
manufacturer (Ettan
TM DIGE Basic course, GE healthcare) with
some minor adaptations. Labeling of 50 mg of proteins was
accomplished with 300 pmol of Cy3 or Cy5 in dimethylforma-
mide (DMF, Acros organics). The pooled internal standard,
containing identical protein amounts from all samples, was labeled
with Cy2. To avoid dye specific labeling artifacts, there was a dye
swap in each group (three samples from any condition were never
labeled all with Cy3 or Cy5).
2D-GE
For isoelectric focusing (IEF), a 3–10 NL IPG strip of 24 cm
(GE Healthcare) was rehydrated for 8 hours. IEF runs (IPGphor 3,
GE Healthcare) and preparation of second dimension SDS-PAGE
gels was done according to the manufacturer’s Ettan
TM DIGE
Basic course (GE healthcare). Strip equilibration was carried out
with equilibration buffer I and II (6 M urea, 2% SDS, 50 mM Tris
pH8.8, 0.02% bromophenol blue and 30% glycerol) containing
1% DTT or 4.5% iodoacetamide respectively. After equilibration,
strips were mounted onto the SDS-PAGE gels (12.5%), and run
for 2 hours at 5 mA/gel and overnight at 25 mA/gel in the Ettan
DALTsix electrophoresis system (GE healthcare). 26 SDS
electrophoresis buffer was used in the lower buffer chamber and
36SDS electrophoresis buffer in the upper buffer chamber.
2D-DIGE analysis
CyDye-labeled 2D-DIGE gels were scanned on the Ettan DIGE
imager (GE healthcare). Gel images from all three CyDyes were
loaded into DeCyder 7.0 software (GE healthcare) and analyzed.
Statistical significance was calculated using Student’s t test and
analysis of variance (ANOVA) to compare the variation in
abundance within a group to the magnitude of change between
groups. Spots present in 85% of the gel images, and with a
statistically significant ANOVA (p#0.05) were considered for
further analysis. Unsupervised principal component analysis (PCA)
was performed using the DeCyder extended data analysis (EDA)
module.
Spotpicking and protein digestion
For spot picking (Ettan SpotPicker, GE healthcare) a prepar-
ative gel was made containing 200 mg of an unlabeled sample and
50 mg of the labeled internal standard. Bind-silane (GE healthcare)
and reference stickers were applied on the glass plate containing
spacers before pouring the gel, thereby ensuring the accuracy of
robotic protein excision. In-gel digestion using trypsin (Promega)
was performed manually as described by Shevchenko [39].
Mass spectrometric analysis and protein identification
The mass spectrometer was calibrated and tuned as described in
LCQ ‘Operator’s Manual’ Revision B July 1996. Instrumental ion
optics were further optimized for analysis of doubly charged
peptide ions by direct infusion (1 ml/minute) of synthetic peptide
‘IFGKGTTLSVSSNIQ’ at 10 pmol/ml in 0.1 M acetic acid
([M+2H]
2+=776.42). Tryptic digests were dried in vacuo, solubi-
lized in 20 ml 0.1 M acetic acid in water containing cortisol (4 pg/
ml) as an internal standard and analyzed in data-dependent mode
by nanoflow HPLC/ESI(+)-MS/MS [40]. Stability of the
chromatographic process and ESI efficiency were monitored
using cortisol base peak m/z 361.2. Bovine serum albumin (10
fmole BSA on-column) was used for analytical system control.
LCQ Xcalibur v2.0 SR2 raw files and spectra were selected from
within Proteome Discoverer 1.0.0.43 (Thermo Electron) with
following settings: minimal peak count, 50; total intensity
threshold, 4000; and S/N, 6. Peak lists were searched with
Sequest v1.0.43 and Mascot v2.2.0.2 against the EMBL-EBI
International Protein Index database for rat (v3.69; 39578 entries)
and for mouse (v3.69; 56737 entries) both with following settings:
Figure 10. Myelin phagocytosis assay. The influence of paxillin, a
specific blocker of the KCNMA1 channel, on myelin phagocytosis was
studied to evaluate the possible biological involvement of this protein
in EAE and/or MS related disease processes. After macrophage
activation, myelin and paxillin were added and phagocytosis was
measured by flow cytometry.
doi:10.1371/journal.pone.0035544.g010
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3.0 Da (monoisotopic); fixed modifications, carbamidomethylation
of cystein; variable modifications, oxidation of methionin; max
missed cleavages, 2. Outcome of both search engines was validated
with Scaffold v.3.00.03 (Proteome Software) with minimum
peptide and protein probability set to 95% and 99.9% respectively.
The protein identifications thus returned by Scaffold for each gel
spot were manually validated considering spectral quality.
HASH in TRANCHE representing our data: nq+91eLffYI-
LUDgesGy6Hx/mmDF6a7hPyvCMAdFcKwBUafN2Dr6-
DUlM0HaKPWb5XYiVh/nbmTKuRAL+sxbLFD4FyzT-
wAAAAAAAAEcQ= =
Immunohistochemistry
Tissue sections (10 mm, Leica CM1900 UV microtome) of the
spinal cord were used for IHC. Macrophages were detected with
the ED-1 staining (mouse anti-rat CD68, AbD serotec) as a
primary antibody (1/200, 2 hours). Myelin protein 29,3 9-cyclic
nucleotide 39-phosphodiesterase (CNP) was detected using mouse
anti-CNP (Millipore) as a primary antibody (1/200, overnight).
Biotinylated polyclonal rabbit anti-mouse IgG (Dako) was selected
as secondary AB (1/400, 1 hour). 10% rabbit serum was chosen
for blocking and 3,39-diaminobenzidine (DAB) for staining.
Hematoxylin was used as a counterstaining. For the analysis of
the staining (Nikon ECLIPSE 80i microscope, NIS elements
software, 206 objective), 3 ED-1 stained tissue sections were
scanned for positive staining regions. These regions were defined
as inflammatory plaques, and pictures were taken of these areas.
Macrophage infiltration was defined as the percentage of positive
area in these pictures. For the CNP staining, 3 slices adjacent to
the 3 slices stained for macrophages were used. CNP was
measured in the area corresponding to the inflammatory plaques
in the ED-1 stained slices. Statistical analysis of the difference in
macrophage infiltration and CNP expression between the
experimental groups was done using Dunn’s multiple comparison
test (GraphPad Prism4).
Western blotting
7.5 mg of the brainstem protein extract was separated by 1D
SDS-PAGE. After blotting to a nitrocellulose membrane, total
protein staining was done by means of ruthenium (II) tris
(bathophenantroline disulfonate)(RuBPS) staining (Rubilab) as
previously described [41]. A subsequent immunostaining was
performed with mouse anti-CNP (Millipore, 1/2500 for 1 hour),
rabbit anti-DLG4 (Millipore, 1/1000 for 2 hours) and rabbit anti-
KCNMA1 (Millipore, 1/1000 for 2 hours) as primary antibodies.
Goat anti-mouse/rabbit Alexa fluor 647 (Invitrogen) were used as
a secondary antibody (1/5000, 2 hours). The fluorescent signal
was measured with the Ettan DIGE scanner and imagequant TL
software was used for processing (GE healthcare). The immuno-
staining intensities were normalized for unequal protein load
(fluorescent total protein stain). The peak volume was used for
quantification.
Network analysis
Mapping of proteins identified by mass spectrometry onto
existing networks and pathways was accomplished using Ingenuity
Pathway Analysis software (IngenuityH Systems, www.ingenuity.
com). The data set containing protein identities was uploaded into
the software. Networks of the identified proteins containing the
molecular relationships between genes/gene products were
generated algorithmically using the Ingenuity Pathway knowledge
base (IPA-KB). Nodes represent genes or gene products and are
displayed using various shapes that represent the functional class of
the gene product. Nodes are connected by edges (lines) which
represent different biological relationships that were in to IPA-KB
at the time of creation. In addition, in order to evaluate the
overlap of the current work with MS, lists of biological markers
were obtained from the IPA-KB as well as from a competitor
product GeneGO Metasearch (GeneGo, St. Joseph, MI, USA)
and are used for comparison to our data.
Ingenuity Pathway Analysis has been designed to work with
human, mouse and rat models. However, in order to support the
discussion of MS in human, we decided to use human gene-names
in this work. Therefore, all graphs presented in this report contain
human nomenclature.
Myelin phagocytosis assay
Rat macrophages (NR8383 cell line) were cultured in RPMI
1640 medium (Invitrogen) enriched with 10% fetal calf serum
(Hyclone, Erenbodegen, Belgium), 50 U/ml penicillin and 50 U/
ml streptomycin (Invitrogen). Macrophages were activated with
100 ng/ml lipopolysaccharide (LPS, Sigma) for 18 hours. Next,
100 mg/ml DiI-labeled myelin, isolated and labeled as described
previously [42] and paxillin (Sigma) were added for 90 minutes.
For paxillin treatment a concentration of 300 nM was used to
obtain a total blockage of the KCNMA1 channel [43]. Flow
cytometry was used to assess the degree of myelin internalization.
Supporting Information
Table S1 Protein identifications. Differential protein spots
were picked and in-gel digestion was performed. Proteins were
identified by mass spectrometry.
(XLSX)
Table S2 Cluster analysis. A cluster analysis was performed
to get a better view on the expression profile of these spots along
the disease course. The average ratio and T-test, for the six
possible comparisons between the four conditions included in this
study, provides detailed information on the time course of the
proteome changes induced in the inflamed brain.
(XLSX)
Table S3 IPA networks. In this table an overview is presented
of all 75 unique proteins and their presence in the IPA networks
presented in Figure 8.
(XLSX)
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